Theravance Biopharma Inc. (TBPH)
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Company Participants Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - Senior VP & CFO Rhonda F. Farnum - Chief Business Officer and Senior VP of Commercial & Medical Affairs Rick E.
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.13 per share a year ago.
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial officer Aine Miller - Head-Development Conference Call Participants Marc Frahm - TD Cowen Operator Hello, ladies and gentlemen. Good afternoon.
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago.
Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance's Q4 Loss In Line With Estimates, Sales Beat
TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.
Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Officer Aziz Sawaf – Chief Financial officer Aine Miller – Head-Development Conference Call Participants Douglas Tsao – H.C. Wainwright Julian Harrison – BTIG David Risinger – Leerink Partners Operator Ladies and gentlemen, good afternoon.
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.03 per share a year ago.
